User profiles for "author:Pedro Berraondo"
Pedro Berraondo LópezCima Universidad de Navarra Verified email at unav.es Cited by 8133 |
[HTML][HTML] Cytokines in clinical cancer immunotherapy
P Berraondo, MF Sanmamed, MC Ochoa… - British journal of …, 2019 - nature.com
Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the
discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal …
discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal …
IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy
A Teijeira, S Garasa, MC Ochoa, M Villalba… - Clinical Cancer …, 2021 - AACR
One of the most important mechanisms by which cancer fosters its own development is the
generation of an immune microenvironment that inhibits or impairs antitumor immune …
generation of an immune microenvironment that inhibits or impairs antitumor immune …
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
MC Ochoa, L Minute, I Rodriguez… - Immunology and cell …, 2017 - Wiley Online Library
Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells
coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of …
coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of …
[PDF][PDF] CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity
Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz… - Immunity, 2020 - cell.com
Neutrophils are expanded and abundant in cancer-bearing hosts. Under the influence of
CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced …
CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced …
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
KA Schalper, ME Rodriguez-Ruiz, R Diez-Valle… - Nature medicine, 2019 - nature.com
Glioblastoma is the most common primary central nervous system malignancy and has a
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …
poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant …
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa… - Nature, 2019 - nature.com
Abstract Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and
ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung …
ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung …
Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)
C Alfaro, A Teijeira, C Ońate, G Perez… - Clinical Cancer …, 2016 - AACR
Purpose: Myeloid-derived suppressor cells (MDSC) are considered an important T-cell
immunosuppressive component in cancer-bearing hosts. The factors that attract these cells …
immunosuppressive component in cancer-bearing hosts. The factors that attract these cells …
An RNA toolbox for cancer immunotherapy
Cancer immunotherapy has revolutionized oncology practice. However, current protein and
cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for …
cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for …
Targeting NK-cell checkpoints for cancer immunotherapy
A Muntasell, MC Ochoa, L Cordeiro… - Current opinion in …, 2017 - Elsevier
Highlights•NK cells are cytotoxic lymphocytes with potential for cancer immunotherapy.•NK-
cell numbers and function are regulated by surface receptors and cytokines.•Inhibitory and …
cell numbers and function are regulated by surface receptors and cytokines.•Inhibitory and …
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma
I Tirapu, E Huarte, C Guiducci, A Arina, M Zaratiegui… - Cancer research, 2006 - AACR
Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders
them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such …
them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such …